BIOA — Q2 2026 Financial Report Analysis

Overview

BioAge Labs is a clinical-stage drug developer: it has no approved products and earns no money from drug sales, so its quarters are judged on how much cash it spends, how long that cash lasts, and whether its experimental drugs are moving through human trials. In the second quarter of 2026 (April–June), BioAge spent more as its lead drug, BGE-102, moved into a mid-stage trial. Net loss widened 21% to $26.1 million from $21.6 million a year earlier. The cash pile barely moved: it stood at $381.3 million at June 30, versus $384.9 million at March 31, because the company sold new shares during the quarter. Management still says that money funds operations through 2029.

BGE-102 is a once-daily pill that blocks NLRP3, a protein switch inside immune cells that sets off a chain of inflammation. The bet is that turning that switch down can treat diseases driven by chronic inflammation, starting with heart risk in people with obesity and a common diabetic eye disease.

At a glance

• $381.3 million in cash and investments, runway "through 2029" — over three years of funding at the current plan, before any new money is raised.
• BGE-102 direct costs of $11.0 million, up 260% — the drug now takes about two-thirds of the money BioAge spends directly on its programs, as the company concentrates on one asset.
• Loss per share of $0.58 vs $0.60 — this looks better than last year only because there are 25% more shares; the loss in dollars grew 21%.

The numbers

BioAge has no product revenue. The $2.5 million it booked is reimbursement and fees from a research partnership with Novartis, in which BioAge mines its human aging datasets for new drug targets. Novartis was the only source of revenue in both years. That deal can pay up to $20 million in upfront payments and research funding, plus up to $530 million in later milestone payments that depend on outcomes and are not guaranteed.

Where the money went

R&D rose $4.5 million to $24.4 million. The 10-Q breaks out direct spending by program:

The filing attributes the BGE-102 increase to "initiation of QUELL-CV," start-up costs for QUELL-DME, "licensing fees, and drug-product manufacturing." Two lines fell, and those declines hide part of the BGE-102 increase. "Other programs" fell $3.3 million because of "lower licensing costs." Azelaprag, BioAge's former lead obesity drug, cost nothing this quarter because its development was ended in January 2025. Without those declines, total R&D would have grown by roughly twice as much. Spending on BGE-102 alone is now running at more than three times last year's rate.

G&A was flat at $7.4 million: higher stock-based pay was offset by $0.6 million less in legal fees. The legal fees relate partly to an investor lawsuit over the IPO-era statements about azelaprag. A court dismissed that case with prejudice (meaning it cannot be refiled) in March 2026. The plaintiff has appealed to the Ninth Circuit, and any oral argument would likely be in early 2027.

The pipeline: what the cash is buying

A quick guide to trial stages: Phase 1 tests whether a drug is safe and how the body handles it, usually in a few dozen people. Phase 2 tests in patients whether it does what it should and at what dose. Phase 3 is the large trial regulators rely on for approval. BGE-102 has finished Phase 1 and is now entering Phase 2.

• Phase 1 result (April 2026). In participants with obesity and raised inflammation, BGE-102 cut hsCRP by a median 86%, at both 60 mg (21 days) and 120 mg (14 days). hsCRP is a blood marker of inflammation that is linked to heart-attack risk. At 60 mg, 13 of 15 people on the drug ended below 2 mg/L. The company reported no serious adverse events and no dropouts due to side effects. These are short, small studies of a biomarker, not evidence of fewer heart attacks.
• QUELL-CV (Phase 2, first patient dosed June 2026). About 160 adults with obesity and hsCRP above 3 mg/L receive placebo or 30, 60 or 90 mg daily for 12 weeks. The main goal is the percent change in hsCRP, and the trial is meant to pick a dose for later trials. Topline data are guided for the second half of 2026. With first dosing in June and 12 weeks of treatment, enrolment has to move fast to hit that date.
• QUELL-DME (eye disease). Diabetic macular edema (DME) is swelling in the retina caused by leaky blood vessels. It is usually treated with repeated injections into the eye of anti-VEGF drugs, and the filing says about 45% of patients respond poorly to them. In the 10-Q (August), QUELL-DME was a "Phase 1b/2a" trial planned to start mid-2026, with results in mid-2027. An 8-K filed October 2, 2026 gave a revised picture. The first patient has been dosed in what is now described as a randomized Phase 2 trial of about 180 participants in three arms: anti-VEGF plus placebo, anti-VEGF plus BGE-102 90 mg, and BGE-102 alone. The main goal is a change in eyesight at week 12, and topline results are now expected in the second half of 2027. The trial now measures eyesight itself, which is more meaningful than the earlier target-engagement design, but results are now later.
• APJ agonists (obesity, preclinical). These are a pill and a long-acting injectable, plus an antibody optioned from JiKang Therapeutics. BioAge aims to file its first IND, the application to the FDA to start human testing, by year-end 2026.
• Partnerships. BioAge runs a target-discovery collaboration with Novartis and an antibody collaboration with Lilly ExploR&D. Both are early-stage.

What the headline numbers hide

• The stable cash balance came mostly from selling new shares. Cash fell only $3.6 million in the quarter because BioAge sold 1.0 million shares through its "at-the-market" program (selling stock gradually into the market) for $15.6 million net, and employees paid $2.5 million to exercise stock options. Over the first half, operations used $43.3 million of cash. The balance still rose from $285.1 million at year-end 2025 because of a January public offering: 6.78 million shares at $19.50, including the underwriters' extra allotment, for $123.6 million net.
• Dilution is the cost of that cash. Shares outstanding went from 37.4 million at December 31, 2025 to 45.8 million at June 30, 2026, an increase of 22% in six months. That means each existing share owns a smaller slice of the company. Another 9.2 million stock options are outstanding, equal to about 20% of current shares. This is why the loss per share improved while the loss in dollars grew.
• Runway math. "Cash runway" means how long the money lasts at the planned rate of spending. At the first-half operating burn of $43.3 million, about $87 million a year, $381.3 million would last roughly 4.4 years, into 2030. Management only commits to "through 2029", about 3.5 years from June 30, which allows for average spending of up to about $109 million a year. That gap is consistent with costs rising as two Phase 2 trials run at the same time. BioAge has also used up $33.9 million of its $75 million at-the-market program, so it has a ready way to raise more.
• Non-cash and one-off items are small. Stock-based pay was $4.3 million of the $26.1 million loss. Interest income on the cash pile (about $3.4 million) offset part of the spending. The company repaid its term loan on April 1, 2026 and now has no debt. Of a warrant revaluation, only $0.2 million hit the loss. There are no large one-offs in either year's quarter.
• Revenue will not grow into a business. Novartis revenue is cost reimbursement, and $4.4 million of it is already prepaid and sitting as deferred revenue. It reduces the cash burn a little but says nothing about BGE-102's value.

Takeaway: BioAge has turned into a single-drug story. BGE-102 spending more than tripled while other programs were cut back. Equity raises have funded the company into 2029, at the cost of 22% more shares in six months. The QUELL-CV hsCRP readout, guided for the second half of 2026, is the next event that tests whether that bet is right.

Outlook

Management's dated milestones are: QUELL-CV topline data in the second half of 2026; QUELL-DME topline data in the second half of 2027 (pushed back from "mid-2027" in the August filings after the trial was redesigned into a larger Phase 2); and a first APJ IND by the end of 2026. Expect quarterly losses to keep rising from here as both Phase 2 trials enroll at the same time. The first-half direct BGE-102 spend of $18.8 million is a floor, not a run-rate.

Our read: the balance sheet is not the issue for the next three years. The two risks are scientific and timing-related. On the science, lowering hsCRP is a biomarker, and QUELL-CV will show a dose-response on that marker, not fewer heart attacks. Proving clinical benefit in heart disease would take much larger and costlier trials, which is where a partner would matter. On timing, a second-half-2026 readout from a trial that started dosing in June leaves little room for slippage, and the DME timeline has already moved once. A clean QUELL-CV result would most likely be followed by more equity raises, given how actively the company has used its at-the-market program.

Source: BioAge Labs Form 10-Q for the quarter ended June 30, 2026 (filed August 5, 2026); Q2 2026 earnings release (8-K Exhibit 99.1, August 5, 2026); Form 8-K filed October 2, 2026.